Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

48%

REMICADE 507 373 36%

NASONEX 307 284 8%

TEMODAR 236 196 20%

PEGINTRON 225 217 4%

CLARINEX / AERIUS 213 204 4%

FOLLISTIM/PUREGON c/ 145 - N/M

AVELOX 142 115 24%

CLARITIN RX 128 112 14%

NUVARING c/ 96 - N/M

INTEGRILIN 74 84 (13%)

CAELYX 74 62 20%

REMERON c/ 68 - N/M

ZEMURON c/ 63 - N/M

REBETOL 59 71 (17%)

INTRON A 55 60 (8%)

SUBUTEX / SUBOXONE 54 56 (4%)

PROVENTIL / ALBUTEROL CFC 50 53 (5%)

ELOCON 45 36 23%

LIVIAL c/ 45 - N/M

CERAZETTE c/ 44 - N/M

MERCILON c/ 43 - N/M

ASMANEX 42 43 (1%)

IMPLANON c/ 38 - N/M

MARVELON c/ 37 - N/M

NOXAFIL 34 16 115%

FORADIL
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
(Date:8/29/2014)... based on electrons, but one of the most promising ... circuits based on light (photons) instead of electrons. First, ... stream of single photons and control their direction. Researchers ... to achieve this control, but now scientists at the ... stream of photons emitted one at a time and ...
(Date:8/29/2014)... 29, 2014 The global companion ... in 2019. It is expected to grow at ... and was valued at $1.8 billion in 2013, ... Market Research. , For more information regarding analysis ... , The research report, titled “Companion Diagnostics Market ...
(Date:8/29/2014)... 2014 According to a new market report ... orthobiologics market was valued at USD 3,754.6 million in 2012 ... in 2019at a CAGR of 5.9% from 2013 to 2019. ... above is afflicted by bone and joint disorders, and this ... This has and will continue to increase the demand for ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... XIANYANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. ... manufacturer of a leading over-the-counter Hepatitis B medicine, Xin,Aoxing Oleanolic ... announced financial results of the first quarter ended March,31, ... revenue increased 66.0% to $12.4 million, -- ...
... 17 Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the ... first quarter of 2010. , ... Soligenix,s revenues for the first quarter of 2010 were approximately ... of 2009. The decreased revenues were primarily a result of decreases in ...
... and MELVILLE, N.Y. May 16 ... Pharmaceuticals, Inc. (Nasdaq: OSIP ), a biotechnology company primarily focused ... medical needs in oncology, diabetes and obesity, today announced that they ... acquire OSI. , , ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 2Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 3Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 4Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments 5Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 2Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 3Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 4Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 5Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. 6
(Date:8/29/2014)... made some surprising discoveries about the body,s initial ... (SIV), the team found that specialized cells in ... to viral invasion and are the source of ... beta (IL-1β). , Though aimed at the ... gut epithelium that provides a barrier to protect ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... little has been known about what genetic changes transform ... scientists, one of whom is a University of Montana ... genes controlling the development of the brain and the ... study was published Aug. 28 in Science ... online at http://www.sciencemag.org/ ., The domestication of animals ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... from the food industry are excellent sources of proteins ... However, at the moment these side streams are mainly ... end up as waste. Coordinated by VTT, the ... containing industrial co-streams) project seeks to enrich several co-stream ...
... is no scientific evidence that low-level electromagnetic field ... causes adverse health effects, according to a report ... the Committee provides advice to authorities about risk ... has assessed the health hazards from low-level electromagnetic ...
... Mass. and COLUMBIA, S.C., Sept. 17, 2012   Eliza Corporation ... engagement management, and BlueCross BlueShield of South Carolina ... rates for BlueCross members increased 45 percent over 2011 ... 2012 program have exceeded expectations in all areas, and ...
Cached Biology News:Food industry's high-quality co-streams used effectively as raw material for new products 2Mobile phones and wireless networks: No evidence of health risk found 2Mobile phones and wireless networks: No evidence of health risk found 3Mobile phones and wireless networks: No evidence of health risk found 4Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 2Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 3Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent 4
15(S)-HETE-d8 is used as an internal standard for the quantification of 15(S)-HETE by stable isotope dilution mass spectrometry....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: